Physician profile
Sanjay Sarin
NPI 1184800534
$741.69
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.80 · 2020: $146 · 2021: $185 · 2022: $136 · 2023: $93.30 · 2024: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $294.35 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $148.52 | 2019-2022 | |
| Novo Nordisk INC | $65.19 | 2021-2024 | Ozempic, Rybelsus |
| Amgen INC. | $38.73 | 2019-2023 | Repatha |
| Edwards Lifesciences Corporation | $27.62 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $26.91 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.43 | 2024 | Jardiance |
| Cvrx, INC. | $22.25 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.67 | 2020-2022 | |
| Boston Scientific Corporation | $19.16 | 2019 | |
| Chiesi USA, INC. | $18.17 | 2024 | Kengreal |
| Gilead Sciences, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Sarin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.